Download the Free Unbound MEDLINE PubMed App to your smartphone or tablet.
Available for iPhone, iPad, iPod touch, and Android:
Available for Mac and Windows Desktops and laptops:
- Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. [JOURNAL ARTICLE]
- Hosp Pract (1995) 2015 Aug 26.:1-9.
- Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. [JOURNAL ARTICLE]
- Can J Anaesth 2015 Aug 22.
- Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. [JOURNAL ARTICLE]
- Future Oncol 2015 Aug 20.:1-11.
- Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children. [Journal Article]
- J Community Support Oncol 2015 Jun; 13(6):209-13.
- Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. [JOURNAL ARTICLE]
- Support Care Cancer 2015 Aug 12.
- Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. [JOURNAL ARTICLE]
- Support Care Cancer 2015 Aug 6.
- Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. [Journal Article]
- Int J Clin Exp Med 2015; 8(5):7989-94.
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial. [JOURNAL ARTICLE]
- J Obstet Gynaecol Res 2015 Jul 21.
- Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a population with gynecologic malignancy treated with moderately emetic chemotherapy. [JOURNAL ARTICLE]
- J Gynecol Oncol 2015 Jul 20.